The Use of Biologics During the COVID-19 Pandemic
- 1 October 2021
- journal article
- research article
- Published by Elsevier in Dermatologic Clinics
- Vol. 39 (4) , 545-553
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New YorkNew England Journal of Medicine, 2020
- Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatmentJournal of the American Academy of Dermatology, 2020
- Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerationsJournal of the American Academy of Dermatology, 2020
- SARS‐CoV‐2 asymptomatic infection in a patient under treatment with dupilumabJournal of the European Academy of Dermatology and Venereology, 2020
- Safety of dupilumab in severe atopic dermatitis and infection of Covid‐19: two case reportsJournal of the European Academy of Dermatology and Venereology, 2020
- Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern ItalyJournal of Dermatological Treatment, 2020
- Dupilumab and COVID ‐19: What should we expect?Dermatologic Therapy, 2020
- Biologics increase the risk of SARS ‐ CoV ‐2 infection and hospitalization, but not ICU admission and death: Real‐life data from a large cohort during red‐zone declarationDermatologic Therapy, 2020
- COVID-19: risk for cytokine targeting in chronic inflammatory diseases?Nature Reviews Immunology, 2020
- Two Phase 3 Trials of Adalimumab for Hidradenitis SuppurativaNew England Journal of Medicine, 2016